

Supplementary Table 1. Summary of hSBA immunogenicity results (hSBA full analysis set)

	No.	Participants with titers ≥ 8 (95% CI, %)	GMT (95% CI)	GMR ^a (95% CI)
MenA				
1M post-vac	122	94 (88.5-97.7)	107.9 (85.7-135.8)	0.061 (0.048-0.076)
1Y post-vac	114	39 (30.4-49.1)	6.8 (5.2-8.9)	
MenC				
1M post-vac	122	98 (94.2-99.8)	201.0 (157.9-256.0)	0.063 (0.049-0.080)
1Y post-vac	110	61 (51.1-70.1)	13.0 (9.7-17.6)	
MenW				
1M post-vac	122	100 (97.0-100.0)	426.7 (338.3-538.2)	0.12 (0.099-0.15)
1Y post-vac	113	88 (80.1-93.1)	53.6 (40.4-71.0)	
MenY				
1M post-vac	120	100 (97.0-100.0)	359.4 (280.6-460.3)	0.14 (0.11-0.16)
1Y post-vac	114	89 (81.3-93.8)	50.8 (38.8-66.5)	

hSBA, serum bactericidal assay using human complement; CI, confidence interval; GMT, geometric mean titer; GMR, geometric mean ratio; M, month; post-vac, post-vaccination with four MenACWY-CRM doses; Y, year.

^aOne-year vs. 1-month post-vaccination GMT ratio.